Press Release

Printer Friendly VersionView printer-friendly version << Back

Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

NEWARK, Calif., Dec. 5, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York.

Protagonist Therapeutics, Inc. (PRNewsFoto/Protagonist Therapeutics, Inc.)

Presentation details:


BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference


Wednesday, Dec. 12, 2018


9:20 a.m. EST

A live and archived audio webcast of the presentation can be accessed by visiting the Investors page of the Protagonist Therapeutics website at

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-200 is an oral peptide interleukin-23 receptor antagonist in development for the treatment of Crohn's disease, and it has completed Phase 1 studies in healthy volunteers. The company has entered into a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200. PN-10943 is an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide that is under development for treatment of ulcerative colitis. Protagonist is also developing an injectable hepcidin mimetic, PTG-300, for the potential treatment of anemia and iron overload related to rare blood diseases with an initial focus on beta thalassemia. A global Phase 2 trial in patients with beta thalassemia will be initiated by the end of 2018.

Protagonist is headquartered in Newark, California, with pre-clinical and clinical staff in California and discovery operations in both California and Brisbane, Queensland, Australia. For further information, please visit

Cision View original content to download multimedia:

SOURCE Protagonist Therapeutics, Inc.

Solebury Trout, Rich Allan (media), Tel: +1 646-378-2958, Email: or Marcy Nanus (investors), Tel: +1 646-378-2927, Email: